Soft Tissue Sarcoma Page 1 of 2 Metastatic or Desmoid Localized Localized Tumor/Aggressive Unresectable Resectable Fibromatosis See Page 2 No Prior Prior Epitheliod or Anthracyline Anthracyline Chordoma IRB# 19313 IRB# 23061 A Phase 3 Trial of A Phase 2/3, Nirogacestat Randomized, versus Placebo in Multicenter Study IRB# 20087 Adult Patients to Evaluate AL102 GSK208467: Open- with Progressing in Patients with Label Multi-cohort Refractory Liposarcoma Rhabdo INI1 Pos DesmoidTumors/A Progressing Clinical Trial to Assess ggressive Desmoid Tumors the Safety and Fibromatosis Antitumor Activity of Genetically Engineered NY-ESO-1- Specific (c259) T Cells, IRB# 10529 IRB# 15649 alone or in IRB# 23208 SARC024: A EZH-202: A Phase combination with A Multicenter blanket protocol 2, Multicenter other agents, in HLA- Phase 1, Open- to study oral Study of the EZH2 A2+ Participants with Label Study of regorafenib in Inhibitor NY-ESO-1 and/or SQ3370 in Patients patients with Tazemetostat in LAGE-1a Positive with Advanced refractory Adult Subjects Solid Tumors Solid Tumors liposarcoma, with INI1-Negative osteogenic Tumors or sarcoma, and Relapsed/Refracto Ewing/Ewing–like ry Synovial sarcomas Sarcoma 23 Jul 2021 Soft Tissue Sarcoma Page 2 of 2 Diffuse Localized Tenosynovial Giant Resectable Cell Tumor SARCOMA SURVIVORS: IRB# 20946 IRB# 21824 Phase 1, Open- A Phase 4, IRB# 19942 IRB# 10529 Label Study of DCC- Multicenter Study A resistance Sarcoma Survivors 3014 to Assess the to Evaluate training program Registry Safety, Tolerability, Discontinuation to improve Pharmacokinetics, Other Soft Primary tumor Retroperitoneal and Re-Treatment physical function in and Tissue Sarcoma >5cm Liposarcoma in Subjects with sarcoma survivors Pharmacodynamics Tenosynovial Giant in Patients with Cell Tumor Advanced Tumors - (TGCT) Previously Expansion Phase IRB# 17895 IRB# 21322 Treated with IRB#17190 Cohort B (TGCT) Local injection of Phase III Study of Pexidartinib A Phase 1B trial anti-cancer drugs Preoperative vs of eribulin and using Presage’s Postoperative radiation for CIVO™ device in Intensity retroperitoneal soft tissue Modulated liposarcoma IRB# 18118 CROSS-DISEASE TRIALS: sarcoma patients Radiation Therapy A PHASE 1/2 DOSE undergoing for ESCALATION AND DOSE EXPANSION IRB# 19991 IRB# 18084 IRB# 20679 surgery Truncal/Extremity STUDY OF BA3011 EAY131 S1609 (DART) SMMART: ACT Soft Tissue ALONE AND IN (MATCH) Sarcoma COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS 23 Jul 2021 .